Management Team

Alan Collier

Chairman, Chief Executive Officer & Interim Chief Financial Officer

Mr. Collier has more than twenty years of experience in corporate finance, IP development, telecommunications and technology with a concentration in healthcare and technology over the last five years. Prior to his appointment as Endonovo’s CEO and chairman, Mr. Collier served as CEO and director of IP Resources International, Inc. where he was instrumental in developing a platform for for the licensing and acquisition of life science and technology companies.

Previously, Mr. Collier served as a Senior Managing Director at Mid-Market Securities, a FINRA-registered Broker-Dealer. Prior to joining Mid-Market Securities, Mr. Collier was a Managing Director at Mosaic capital and co-managed its Capital Markets Group. He was previously a Vice President at Corporate Capital Group and Managing Director and CEO of Greenbridge Capital Group.

Over the progression of his career, he has specialized in the development and financing of early stage, high growth, and acquisitive companies (public and private). He has structured, participated in, and completed numerous transactions including mergers and acquisitions, equity and debt placements, capital restructuring, joint venture development, and channel partner procurement. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Mr. Collier has previously held FINRA Series 7, 79, 63, and 24 Licenses.

Michael Mann


Mr. Mann has over 30 years experience in merger and acquisitions and operational management. In 2008 Mr. Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics, Inc,. and led the company to become listed on the OTCBB in 2012.

From January 2003 to April, 2011, Mr. Mann was the Founder, President and Chief Executive Officer of U.S. Debt Settlement, Inc. (USDS), a Frankfurt listed company, where he implemented a growth by acquisition strategy successfully acquiring numerous companies.

From January 2002 to July 2003, Mr. Mann was the Chief Executive Officer of Shared Vision Capital, a boutique investment banking firm that assisted emerging companies with early seed capital and bridge loans. Earlier still, from October 1998 to December 2001, Mr. Mann was the Vice President of Investor Relations for, an online legal research platform. During his tenure with, Mr. Mann was directly responsible for funding the company’s growth and development. In addition, Mr. Mann founded Universal Pacific Communications, a privately owned telecommunications company. Under his leadership as President, Universal Pacific developed a fiber optic disaster recovery telecommunications network, designed for and successfully marketed to Fortune 1000 companies.

Don Calabria

Chief Operating Officer

Mr. Calabria brings over seventeen years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance, and business development. Mr. Calabria has a deep level of experience in analyzing companies, determining the operational efficiencies, and conducting operational due diligence on targeted acquisitions.

Previously, Mr. Calabria served as President of Gemini Consulting Group, Inc., a boutique consulting firm which specialized in providing consulting services to companies in multiple marker segments with a core focus directed towards capital structuring and investments, brand strategy and marketing, M&A activities, and operational efficiencies. Prior to this, Mr. Calabria was the VP of Operations for TrinTel Communications; the largest privately held Infrastructure Company in the wireless telecommunications industry. As part of the Company’s initial Senior Management team, which grew the company to a $350+ million valuation in under three years, Mr. Calabria specialized in managing joint venture agreements and strategic alliances as well as directing all subsidiary operations including regional sales, marketing, and business development practices. Prior to this, as the Director of Operations for Wireless Solutions, LLC, he helped facilitate the sale of the company to TrinTel Communications.

Mr. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a BS in Management from Arizona State University.

Nevena Zubcevik, DO, MSPT, ATC

Chief Medical Officer

Dr. Zubcevik has over 24 years experience in the medical field, 17 of which are in clinical development, and is a licensed physician and educator. Prior to Endonovo, Dr. Zubcevik was an Attending Physician at Harvard Medical School/Partners HealthCare in the Physical Medicine and Rehabilitation Department. During her tenure at Harvard, Dr. Zubcevik was involved in innovation in both the clinical and research arenas, serving as a Principal Investigator to clinical trials and Clinical co-Director. She was also an Executive Director at LIV NGO, a non-profit organization.

David Clark

Vice President of Sales

Mr. Clark has 25 years of surgical device commercial experience with leading companies, including Medtronic and Baxter. Mr. Clark was most recently Executive Vice President of Sales for Biom’up, including the launch of surgical hemostat HEMOBLAST Bellows™. He built and led the U.S. Biom’up Sales Team, consisting of 200 plus in-direct sales representatives and direct commercial leaders. David holds a B.A. in Economics from Rutgers University.

Steven Ford

Vice President of Marketing

Mr. Ford has 25 years of surgical device commercial experience with leading companies, including Allergan, Ethicon, Bard & Baxter. Most recently, Mr. Ford was the U.S. Vice President of Marketing for Biom’up, where he launched the surgical hemostat HEMOBLAST Bellows™. Steven’s career includes the launch of over 50 medical devices globally as well as having participated and led over 75 product development teams. Steven holds a B.S. in Marketing from California State University.